Ranbaxy Laboratories Limited SWOT Analysis-Pharmaceuticals Industry

Ranbaxy Laboratories Limited SWOT Analysis-Pharmaceuticals Industry Dissertation Writing Help

 Strengths

Strong commercial infrastructure in emerging markets driving hybrid business growth Daiichi Sankyo, the parent company of Ranbaxy, derives advantage from Ranbaxy's significant presence in emerging pharmaceutical markets in Asia, Africa and East Europe. In the recent years, Ranbaxy introduced several Daiichi Sankyo's innovative products in some markets, starting with India. For instance, in 2009, Ranbaxy began marketing Daiichi Sankyo's Olmesartan (Olvance) in India. In addition, both the companies have formed partnerships in Romania, Mexico and Africa. In December 2011, Daiichi Sankyo and Ranbaxy undertook a synergistic initiative in Malaysia, where Ranbaxy marketed innovative products originally discovered by Daiichi Sankyo.

Ranbaxy is among the very few global generic companies offering a basket of both generic and innovator medicines. The hybrid business model with Daiichi Sankyo has made progress with collaborations on the front-end in Romania, Germany, Venezuela and Thailand in the recent years. Further, under an agreement with Daiichi Sankyo, Ranbaxy launched an authorized generic of Evoxac in the US market during FY2012.

Growing global pharmaceutical business imparting revenue stability

Ranbaxy's growing global pharmaceutical business adds up to the financial growth of the company.

During FY2012, the pharmaceutical segment recorded revenues of INR124,597.3 million (approximately $2,317.5 million), an increase of 20.6% over FY2011. The company’s generic atorvastatin contributed substantially to the US revenues. Ranbaxy achieved a market share of over 50% during the exclusivity period and continued to lead, post exclusivity. Further, in FY2012, growth in Western Europe was aided by the launch of atorvastatin in the region and had secured a significant market share of atorvastatin in Germany, Italy, Sweden, the Netherlands and France.

In August 2012, Ranbaxy Pharmaceuticals Inc. (RPI), a wholly-owned subsidiary of Ranbaxy launched authorized generic pioglitazone hydrochloride tablets in the US market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc. This was a significant addition to the company’s existing portfolio of anti-diabetic products in the US market. The branded segment, which is the one of the company’s propellers in the US pharmaceuticals market, launched Absorica (Isotretinoin) capsules under a licensing agreement with Cipher Pharmaceuticals Inc.

Later in October 2012, RPI launched the authorized generic cevimeline hydrochloride 30 mg. capsules in the US market, under an agreement with Daiichi Sankyo. In addition, in April 2012, Ranbaxy launched India's first new drug Synriam for the treatment of uncomplicated Plasmodium falciparum malaria in adults.

Ranbaxy commenced the US launch of three First-To-File (FTF) products during 2009, Sumatriptan, Valacyclovir and Oxcarbazepine Suspension. In Europe, the company launched six new products. In addition, a new Dosage Forms facility was set up in the Special Economic Zone, at Mohali (Punjab, India). The new commercial facility has a capacity of 2 billion tablets and 500 million capsules per annum. This facility would cater to the developed markets of the US and the EU. Also in April 2012,  Ranbaxy commenced exports of Atorvastatin Calcium Oral Tablets to the US market from its Mohali SEZ manufacturing facility. The company has also invested in its manufacturing facilities at Ohm Laboratories, the US, to significantly enhance manufacturing capacities in 2010. Thus, the strong growth witnessed in the pharmaceutical business imparts financial stability to the company and strengthens its hold in the market.

Focus in diverse therapeutic and geographic areas providing competitive advantage

Ranbaxy focuses in a wide range of therapeutic areas, which insulates its business from concentration

risk and provides it with competitive advantage. The company offers active pharmaceuticals ingredients (API) and intermediate, generics, drug discovery and consumer health care products. The company's products are divided into two general areas: dosage forms and API. The company offers therapeutics for orthopedics, pain management, and gastrointestinal, cardiovascular and central nervous system disorders. In addition, Ranbaxy offers nutritionals, multivitamins and dermatologicals. Its API division offers about 50 products covering a wide therapeutic range such as cardiovasculars, anti-infectives, anti-ulcerants, anti-diabetics, anti-depressants, anti-virals and others.

Ranbaxy generates revenues from diverse markets across the globe. The company has strong presence in both developed and emerging markets. It has a significant presence in 23 of the top 25 pharmaceutical markets of the world. Ranbaxy serves its customers in over 125 countries and has  an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in eight countries. During FY2012, Ranbaxy derived 18.7% of its total revenues from India, its domestic market, 43.2% from North America, 16.8% from the European market, 6.3% from Africa, 6.7% from Asia Pacific other than India and the remaining from other regions. Strong presence in geographically diverse markets shields Ranbaxy from risks associated with adverse economic and political developments in a particular geographic region.

If you want Dissertation Writing Help, Assignments, Essays or Research Proposal on Ranbaxy Laboratories Limited SWOT Analysis-Pharmaceuticals Industry, than contact  http://www.mahasagarpublications.com or Call +91 9819650213 or +91 8081344446 or use the contact form given below.